These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Chemotherapy for small cell bronchogenic carcinoma: CCNU and doxorubicin compared to CCNU, doxorubicin, vincristine, and procarbazine.
    Author: Vogelzang NJ, Trowbridge RC, Frenning DH, Theologides A, Kennedy BJ, Kelly DR, Ewing SL, Vosika GJ.
    Journal: Cancer Treat Rep; 1980; 64(8-9):997-1000. PubMed ID: 6256076.
    Abstract:
    Forty consecutive patients with small cell bronchogenic carcinoma were treated. The first 18 patients were treated with CCNU and doxorubicin (Adriamycin) (CA). The next 22 patients were treated with CCNU, doxorubicin, procarbazine, and vincristine (CAPO). Patient characteristics were similar. The partial plus complete response rate was 55% (ten of 18 patients) in the CA group compared to 41% (nine of 22 patients) in the CAPO group. The median survival from treatment was 28 weeks in the CA group compared to 33 weeks in the CAPO group. There were no drug-related deaths among the patients receiving CA compared to two definite and three probably drug-related deaths among the patients receiving CAPO. The addition of procarbazine and vincristine to CA for the treatment of small cell bronchogenic carcinoma resulted in increased toxicity and no survival benefit.
    [Abstract] [Full Text] [Related] [New Search]